Padala SA, Barsouk A, Thandra KC et al (2020) Epidemiology of renal cell carcinoma. World J Oncol 11(3):79–87. https://doi.org/10.14740/wjon1279

Article  PubMed  PubMed Central  Google Scholar 

Sung H, Ferlay J, Siegel R et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

Article  CAS  PubMed  Google Scholar 

Dudani S, de Velasco G, Wells JC et al (2021) Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open 4(1):e2021869. https://doi.org/10.1001/jamanetworkopen.2020.21869

Article  PubMed  PubMed Central  Google Scholar 

Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134. https://doi.org/10.1056/NEJMoa060655

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. https://doi.org/10.1056/NEJMoa065044

Article  CAS  PubMed  Google Scholar 

Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281. https://doi.org/10.1056/NEJMoa066838

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456. https://doi.org/10.1016/S0140-6736(08)61039-9

Article  CAS  PubMed  Google Scholar 

Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813. https://doi.org/10.1056/NEJMoa1510665

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290. https://doi.org/10.1056/NEJMoa1712126

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116–1127. https://doi.org/10.1056/NEJMoa1816714

Article  CAS  PubMed  Google Scholar 

Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384(9):829–841. https://doi.org/10.1056/NEJMoa2026982

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer R, Alekseev B, Rha SY et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384(14):1289–1300. https://doi.org/10.1056/NEJMoa2035716

Article  CAS  PubMed  Google Scholar 

Albigès L, Bellera C, Branchoux S et al (2024) Real-world treatment patterns and effectiveness of patients with advanced renal cell carcinoma: a nationwide observational study. Clin Genitourin Cancer 22(2):295-304.e6. https://doi.org/10.1016/j.clgc.2023.11.012

Article  PubMed  Google Scholar 

Gouverneur A, Salvo F, Berdaï D et al (2018) Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: a systematic review. J Geriatr Oncol 9(1):15–23. https://doi.org/10.1016/j.jgo.2017.08.001

Article  PubMed  Google Scholar 

Mitchell AP, Harrison MR, Walker MS et al (2015) Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice. J Oncol Pract 11(6):491–497. https://doi.org/10.1200/JOP.2015.004929

Article  PubMed  Google Scholar 

Heng DY, Choueiri TK, Rini BI et al (2014) Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 25(1):149–154. https://doi.org/10.1093/annonc/mdt492

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ishihara H, Nemoto Y, Nakamura K et al (2023) Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: a real-world retrospective multi-institutional study. Target Oncol 18(2):209–220. https://doi.org/10.1007/s11523-023-00956-8

Article  PubMed  Google Scholar 

Gan CL, Stukalin I, Meyers DE et al (2021) Outcomes of patients with solid tumour malignancies treated with first-line immune-oncology agents who do not meet eligibility criteria for clinical trials. Eur J Cancer 151:115–125. https://doi.org/10.1016/j.ejca.2021.04.004

Article  CAS  PubMed  Google Scholar 

Marschner N, Staehler M, Müller L et al (2017) Survival of patients with advanced or metastatic renal cell carcinoma in routine practice differs from that in clinical trials-analysis from the German clinical RCC registry. Clin Genitourin Cancer 15(2):e209–e215. https://doi.org/10.1016/j.clgc.2016.08.022

Article  PubMed  Google Scholar 

Chari A, Romanus D, Palumbo A et al (2020) Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 20(1):8-17.e16. https://doi.org/10.1016/j.clml.2019.09.625

Article  PubMed  Google Scholar 

Kawachi H, Fujimoto D, Morimoto T et al (2018) Clinical characteristics and prognosis of patients with advanced non-small-cell lung cancer who are ineligible for clinical trials. Clin Lung Cancer 19(5):e721–e734. https://doi.org/10.1016/j.cllc.2018.05.014

Article  PubMed  Google Scholar 

Vaishampayan U, Vankayala H, Vigneau FD et al (2014) The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database. Clin Genitourin Cancer 12(2):124–129. https://doi.org/10.1016/j.clgc.2013.09.007

Article  PubMed  Google Scholar 

Li P, Wong YN, Armstrong K et al (2016) Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy era. Cancer Med 5(2):169–181. https://doi.org/10.1002/cam4.574

Article  PubMed  Google Scholar 

Pal SK, Ghate SR, Li N et al (2017) Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: a SEER-medicare database analysis. Clin Genitourin Cancer 15(4):e573–e582. https://doi.org/10.1016/j.clgc.2016.12.005

Article  PubMed  Google Scholar 

Ishihara H, Takagi T, Kondo T et al (2021) Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: as retrospective analysis of real-world data. Jpn J Clin Oncol 51(5):793–801. https://doi.org/10.1093/jjco/hyaa232

Article  PubMed  Google Scholar 

Esterberg E, Iyer S, Nagar SP et al (2024) Real-world treatment patterns and clinical outcomes among patients with advanced renal cell carcinoma. Clin Genitourin Cancer 22(2):115-125.e3. https://doi.org/10.1016/j.clgc.2023.09.009

Article  PubMed  Google Scholar 

Hara T, Miyake H (2025) The role of cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a review of current evidence and ongoing trials. Int J Urol 32(1):7–14. https://doi.org/10.1111/iju.15594

Article  CAS  PubMed  Google Scholar 

Kanzaki R, Higashiyama M, Fujiwara A et al (2011) Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: a 25-year single-institution experience. Eur J Cardiothorac Surg 39(2):167–172. https://doi.org/10.1016/j.ejcts.2010.05.021

Article